



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/688,016	10/15/2003	Thomas J. Caggiano	08702.0007-02000	4399
22852	7590	01/31/2005	EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			KERR, KATHLEEN M	
			ART UNIT	PAPER NUMBER
			1652	

DATE MAILED: 01/31/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/688,016

Applicant(s)

CAGGIANO ET AL.

Examiner

Kathleen M Kerr

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM
THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 April 2004.
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-55 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☐ Claim(s) _____ is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☒ Claim(s) 1-55 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Application Status

1. Claims 1-55, as originally filed, are pending in the instant application.

Restriction

2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-4, 9-12, 17-20, 25-30, and 50-51, drawn to mammalian rapamycin effector proteins and related proteins, classified in class 530, subclass 350.
 - II. Claims 5-8, 13-16, 21-24, 31-38, and 52-55, drawn to DNA encoding mammalian rapamycin effector proteins and related polynucleotides, classified in class 536, subclass 23.5.
 - III. Claim 39, drawn to methods for isolating mammalian rapamycin effector proteins, classified in class 530, subclass 413.
 - IV. Claims 40-41, drawn to methods for identifying agents that bind to rapamycin effector proteins, classified in class 435, subclass 7.8.
 - V. Claims 42-43, drawn to methods for identifying agents that modulate the activity of rapamycin effector proteins, classified in class 435, subclass 7.71.
 - VI. Claims 44-45, drawn to methods for identifying the presence of rapamycin and analogs thereof using rapamycin effector proteins, classified in class 435, subclass 7.8.
 - VII. Claims 46-49, drawn to methods for modulating the immune system using antisense, classified in class 514, subclass 44.

3. The inventions are distinct, each from the other because of the following reasons:

The DNA of Group II are related to the proteins of Group I by virtue of the fact that the DNA encode the proteins. The DNA molecule has utility for the recombinant production of the protein in a host cell. Although the DNA and the protein are related, they are distinct inventions because they are wholly different in structure and function. A DNA's structure is comprised of linear, contiguous nucleotides while a protein's structure comprised of linear, contiguous amino acids that fold into a specific three-dimensional structure; the DNA's function is to encode a protein while a protein's function is variable, and in this case, to effect rapamycin. Therefore, Group I is patentably distinct from Group II. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper. To search Groups I and II together would present a search burden on the Examiner due to the extensive databases of non-patent literature. For example, claims in Group I, drawn to polypeptides, must be searched not only in commercial amino acid sequence databases, but also in textual databases because isolated polypeptides are often disclosed without the benefit of sequence information although the amino acid sequence is inherently the same as the sequence claimed. Additionally, the nucleic acid sequences must be searched in distinct nucleic acid sequence commercial databases. Thus, Groups I-II have been appropriately restricted on the basis of being both independent or distinct and presenting a search burden on the Examiner if they were to be searched together.

Groups I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be

Art Unit: 1652

made by another and materially different process (M.P.E.P. § 806.05(f)). In the instant case, the proteins can be made by a materially distinct method, such as recombinantly using the known peptide fragments to formulate oligonucleotide probes to screen a mammalian library and identify genes encoding said proteins, wherein said genes can be expressed recombinantly.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Group I is related to Groups IV-VI as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the product can be used for a materially distinct process of using that product, such as in the production of antibodies in vivo. Thus, Group I is patentably distinct from Groups IV-VI. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Group I is related to Group VII by virtue of the fact that the antisense in the methods is related to DNA that encodes the proteins of Group I. However, the proteins are neither made nor used in the claimed methods. Thus, Group I is patentably distinct from Group VII. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1652

Group II is related to Groups III-VI by virtue of the fact that the DNA encode proteins made of used in the methods. However, the DNA itself is neither made nor used in the claimed methods. Thus, Group II is patentably distinct from Groups III-VI. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Group II is related to Group VII as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case, the product can be used for a materially distinct process of using that product, such as in hybridization assays to identify novel rapamycin effect genes. Thus, Group II is patentably distinct from Group VII. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

The methods of Group III are related to the methods of Groups IV-VI by virtue of the fact that the proteins made in Group III can be used in Groups IV-VI. However, these methods are distinct due to their distinct method steps that produce distinct products. Thus, Group III is patentably distinct from Groups IV-VI. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

The methods of Group III are related to the methods of Group VII by virtue of the fact that the proteins made in Group III are encoded by the DNA, whose antisense is used in the

Art Unit: 1652

methods of Group VII. However, these methods are distinct due to their distinct method steps that produce distinct products. Thus, Group III is patentably distinct from Group VII. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Groups IV-VI are related to each other as methods of using rapamycin effector proteins. However, each of the methods is distinct from the other based on distinct method steps to produce distinct products. Groups IV and V both identify modulators of rapamycin effector proteins, but Group IV identifies binding agents while Group V identifies modulators that affect the activity of the protein. Groups IV-V are distinct from Group VI, which identifies the presence of rapamycin in a sample. Thus, each Group of methods use distinct method steps and are distinct from the other Groups. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Moreover, the distinct method steps require distinct keyword searching. Therefore, any two Groups IV-VI would be burdensome if searched together.

Groups IV-VI are related to Group VII because the proteins used in the methods of Groups IV-VI are encoded by DNA whose antisense is used in the methods of Groups VII. However, method steps are wholly distinct using different reagents to produce different products. Thus, Group VII is patentably distinct from Groups IV-VI. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Election of Species

4. This application contains claims directed to the following patentably distinct species of the claimed invention: the 125 kDa protein, the 148 kDa protein, the 208 kDa protein, and the 210 kDa protein. Said species are relevant to every Group delineated above.

These species are patentably distinct, each from the other, based on their distinct structures/characteristics.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Art Unit: 1652

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103(a) of the other invention.

Election

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 C.F.R. § 1.143). Election of species is also required.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(i).

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kathleen M Kerr whose telephone number is (571) 272-0931. The examiner can normally be reached on Monday through Friday, from 9:00am to 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathupura Achutamurthy can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kathleen M Kerr
Primary Examiner
Art Unit 1652



January 24, 2005